316 related articles for article (PubMed ID: 28916655)
1. Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells.
Jounaidi Y; Cotten JF; Miller KW; Forman SA
Cancer Res; 2017 Nov; 77(21):5938-5951. PubMed ID: 28916655
[TBL] [Abstract][Full Text] [Related]
2. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.
Sim GC; Liu C; Wang E; Liu H; Creasy C; Dai Z; Overwijk WW; Roszik J; Marincola F; Hwu P; Grimm E; Radvanyi L
Cancer Immunol Res; 2016 Nov; 4(11):983-994. PubMed ID: 27697858
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
4. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
[TBL] [Abstract][Full Text] [Related]
5.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
6. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
7. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
[TBL] [Abstract][Full Text] [Related]
8. Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy.
Zhang J; Sun R; Wei H; Zhang J; Tian Z
Oncol Rep; 2004 May; 11(5):1097-106. PubMed ID: 15069553
[TBL] [Abstract][Full Text] [Related]
9. Targeting activity of a TCR/IL-2 fusion protein against established tumors.
Wen J; Zhu X; Liu B; You L; Kong L; Lee HI; Han KP; Wong JL; Rhode PR; Wong HC
Cancer Immunol Immunother; 2008 Dec; 57(12):1781-94. PubMed ID: 18369620
[TBL] [Abstract][Full Text] [Related]
10. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
11. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
Garg TK; Szmania SM; Khan JA; Hoering A; Malbrough PA; Moreno-Bost A; Greenway AD; Lingo JD; Li X; Yaccoby S; Suva LJ; Storrie B; Tricot G; Campana D; Shaughnessy JD; Nair BP; Bellamy WT; Epstein J; Barlogie B; van Rhee F
Haematologica; 2012 Sep; 97(9):1348-56. PubMed ID: 22419581
[TBL] [Abstract][Full Text] [Related]
12. Human IL18-IL2 fusion protein as a potential antitumor reagent by enhancing NK cell cytotoxicity and IFN-γ production.
Du G; Ye L; Zhang G; Dong Q; Liu K; Tian J
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1727-36. PubMed ID: 22699929
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells.
Naramura M; Gillies SD; Mendelsohn J; Reisfeld RA; Mueller BM
Immunol Lett; 1993 Dec; 39(1):91-9. PubMed ID: 8144194
[TBL] [Abstract][Full Text] [Related]
14. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
15. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.
Shah N; Martin-Antonio B; Yang H; Ku S; Lee DA; Cooper LJ; Decker WK; Li S; Robinson SN; Sekine T; Parmar S; Gribben J; Wang M; Rezvani K; Yvon E; Najjar A; Burks J; Kaur I; Champlin RE; Bollard CM; Shpall EJ
PLoS One; 2013; 8(10):e76781. PubMed ID: 24204673
[TBL] [Abstract][Full Text] [Related]
16. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
[TBL] [Abstract][Full Text] [Related]
17. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
[TBL] [Abstract][Full Text] [Related]
18. An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack.
Jahn T; Zuther M; Friedrichs B; Heuser C; Guhlke S; Abken H; Hombach AA
PLoS One; 2012; 7(9):e44482. PubMed ID: 23028547
[TBL] [Abstract][Full Text] [Related]
19. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
20. Pan-HDAC inhibitors augment IL2-induced proliferation of NK cells via the JAK2-STAT5B signaling pathway.
Zheng J; Lu Y; Xiao J; Duan Y; Zong S; Chen X; Hu T; Li L; Zhang Y
Int Immunopharmacol; 2023 Mar; 116():109753. PubMed ID: 36738675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
